湖南九典制药股份有限公司 2024 年度独立董事述职报告 （周从山） 各位股东及股东代表： 本人周从山作为湖南九典制药股份有限公司（以下简称"公司"）的独立 董事，严格按照《公司法》《上市公司治理准则》《上市公司独立董事管理办 法》等法律法规和《公司章程》《独立董事工作制度》的要求，忠实、勤勉、 谨慎履行独立董事职责，充分发挥独立董事的独立性、专业性的作用，切实维 护了公司整体利益，维护了全体股东尤其是中小股东的合法权益，对公司的发 展起到了积极的推动作用。现将本人 2024 年度履行独立董事职责的情况汇报如 下： 一、基本情况 本人周从山，1975 年出生，中国国籍，无境外永久居留权，博士研究生学 历，教授，湖南省普通高校学科带头人。2001 年 6 月获得兰州大学物理化学专 业博士学位；2001 年 7 月至今任职于湖南理工学院；现任湖南理工学院化学化 工学院院长。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。 二、2024 年度履职概况 （一）列席股东大会及出席董事会会议情况 1、股东大会 报告期内，公司召开了 2 次股东大会，本人均现场列席了 2 ...

湖南九典制药股份有限公司 2024 年度独立董事述职报告 （阳秋林） 各位股东及股东代表： 作为湖南九典制药股份有限公司（以下简称"公司"）独立董事，本人按照 《公司法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法规和 《公司章程》《独立董事工作制度》的要求，在任职期间积极勤勉履行独立董事 职责，独立、谨慎地行使权利，及时了解公司的经营、财务、内控等动态，出席 公司相关会议并认真审议各项议案，充分发挥了独立董事及相关专业委员会委员 的作用，切实维护全体股东尤其是中小股东的合法权益。现将本人 2024 年履职 情况报告如下： 一、基本情况 本人阳秋林，1964 年出生，中国国籍，无境外永久居留权，工业会计学士， 二级教授，中国注册会计师，湖南省会计学科带头人。1987 年 6 月毕业于湖南 财经学院；1987 年 7 月至今历任南华大学会计系副主任、会计系主任、财务处 副处长、审计处副处长、招投标管理中心主任（处长）、审计处处长、管理学院 副院长（正处级）、会计研究中心主任；2017 年 11 月至 2023 年 11 月任湖南艾 布鲁环保科技股份有限公司独立董事；2020 年 4 月至 2024 ...

湖南九典制药股份有限公司 董事会秘书工作细则 第一章 总则 第一条 为规范湖南九典制药股份有限公司（以下简称"公司"）董事会秘 书的行为，明确董事会秘书的职责权限，根据《中华人民共和国公司法》（以下 简称"《公司法》"）《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）《深圳证券交易所创业板上市公司规范运作指引》（以下简称"《规 范运作指引》"）《湖南九典制药股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，制定本工作细则。 第四条 董事会秘书的任职资格： （一）具有大学专科以上学历，从事经济、管理、证券等工作三年以上； （二）具备履行职责所必须的财务、税收、法律、金融、企业管理等专业知 识； 第三条 董事会秘书是公司与深圳证券交易所（以下简称"深交所"）之间 的指定联络人。 公司应当设立由董事会秘书负责管理的信息披露事务部门，为董事会秘书履 行职责提供便利条件，董事、监事、高级管理人员及公司有关人员应当支持、配 合董事会秘书的工作。 董事会秘书为履行职责有权了解公司的财务和经营情况，参加涉及信息披露 的有关会议，查阅涉及信息披露的所有文件，并要求公司有关部门和人员及时提 供相关 ...

湖南九典制药股份有限公司 媒体采访和投资者调研接待管理制度 第一章 总则 第一条 为维护湖南九典制药股份有限公司（以下简称"公司"）和投资者 的合法权益，加强公司与投资者、媒体等特定对象之间的信息沟通，促进公司诚 信自律、规范运作，并进一步完善公司治理机制，树立和维护良好的企业形象， 结合公司实际情况，制定此制度。 第二条 公司特定对象来访接待工作严格遵守《中华人民共和国公司法》、 《中华人民共和国证券法》等有关法律法规及深圳证券交易所有关业务规则的规 定。 第三条 本规定所称重大信息是指对公司股票及其衍生品种交易价格或者 投资决策可能或者已经产生较大影响的信息，包括下列信息： （一）与公司业绩、利润分配等事项有关的信息，如财务业绩、盈利预测、 利润分配和资本公积金转增股本等； （二）与公司股票发行、回购、股权激励计划等事项有关的信息； （三）与公司收购兼并、资产重组等事项有关的信息； （四）与公司经营事项有关的信息，如开发新产品、新发明，订立未来重大 经营计划，获得专利、政府部门批准，签署重大合同； （五）深圳证券交易所认定的其他机构或者个人。 第五条 本制度适用于湖南九典制药股份有限公司及各子公司。 第二 ...

湖南九典制药股份有限公司 对外投资管理办法 第一章 总则 第一条 为了加强湖南九典制药股份有限公司（以下简称"公司"）对外投 资活动的内部控制，规范对外投资行为，防范对外投资风险，保障对外投资安全， 提高对外投资效益，根据《中华人民共和国公司法》《中华人民共和国证券法》 《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）等有关 法律、法规、规范性文件和《湖南九典制药股份有限公司章程》（以下简称"《公 司章程》"）的规定，制定本办法。 第二条 本办法所称对外投资是指公司在境内外进行的以盈利或保值增值为 目的的投资行为。包括： （一）股权投资（含设立或增资控股或参股企业、国内外收购兼并、合资合 作、对出资企业追加投入等）； （二）金融投资（含证券投资、期货投资、委托理财、债券投资、基金投资 及以股票、利率、汇率和商品为基础的期货、期权、权证等衍生产品投资等）； （三）固定资产投资（含重大固定资产投资、其他固定资产投资等）。 第三条 本办法适用于公司及所属控股企业（以下简称所属企业）所有对外 投资业务。 第四条 公司对外投资必须符合公司的发展战略，坚持成本效益原则，达到 合理投资收益标准，做到为公司全 ...

湖南九典制药股份有限公司 控股子公司管理制度 第一章 总则 第一条 为促进湖南九典制药股份有限公司（以下简称"九典制药"或"公 司"）的规范运作和健康发展，明确公司与各控股子公司财产权益和经营管理责 任，确保控股子公司规范、高效、有序地经营运作，根据《中华人民共和国公司 法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》（以下 简称"《上市规则》"）《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关法律法规及《湖南九典制药股份有限公司章程》 （以下简称"《公司章程》"）的规定，结合公司的实际情况，制定本制度。 第二条 本制度所称控股子公司是指公司持有其 50%以上股份的，或者能够 决定其董事会半数以上成员组成，或者通过协议或者其他安排能够实际控制的具 有独立法人资格的公司。 第三条 控股子公司需遵守公司关于公司治理、关联交易、信息披露、财务 管理、募集资金、对外担保等方面的各项管理制度，做到诚信、公开、透明。 第二章 三会管理 第四条 控股子公司应参照《公司法》《公司章程》的相关规定设立股东会、 董事会（或执行董事）及监事会（或监事）。公司主要通过参与控股子公司股 ...

湖南九典制药股份有限公司 募集资金管理办法 第一章 总则 第一条 为了规范湖南九典制药股份有限公司（以下简称"公司""本公司"） 募集资金的管理和运用，最大程度地保障投资者的利益，依据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规和规范性文件及《湖南九典制药 股份有限公司章程》（以下简称"公司章程"）的规定，结合公司实际情况，特 制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票及其衍生品种，向投资 者募集并用于特定用途的资金，但不包括公司实施股权激励计划募集的资金。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较好的市场前景和盈利能力，有效防范投资风险，提高募集资金使 用效益。 第四条 公司应当建立并完善募集资金存储、使用、变更、监督和责任追究 的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风险控制措施 及信息披露要求。 第五条 公司的董事、监事和高级管理人员应当勤勉尽责，督促上市公司规 范 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,930,677,498.58, an increase of 8.85% compared to ¥2,692,511,461.24 in 2023[15]. - Net profit attributable to shareholders for 2024 was ¥512,377,174.16, representing a 39.13% increase from ¥368,260,790.68 in 2023[15]. - The cash flow from operating activities for 2024 was ¥746,364,584.85, up 73.10% from ¥431,185,028.10 in 2023[15]. - Basic earnings per share for 2024 were ¥1.05, a 36.36% increase from ¥0.77 in 2023[15]. - Total assets at the end of 2024 amounted to ¥3,373,131,232.71, reflecting a 17.48% increase from ¥2,871,199,809.89 at the end of 2023[15]. - The company achieved a consolidated revenue of CNY 293,067.75 million in 2024, representing an 8.85% increase year-over-year[77]. - The net profit attributable to shareholders reached CNY 51,237.72 million, a 39.13% increase compared to the previous year[77]. - The revenue from drug formulations was CNY 2,357,173,125.6, accounting for 80.43% of total revenue, with a growth of 5.40% year-on-year[91]. Dividend Distribution - The company plans to distribute a cash dividend of 3.10 CNY per 10 shares (including tax) based on a total of 495,896,815 shares[3]. - The cash dividend distribution accounts for 100% of the total distributable profit of RMB 512,377,174.16[188]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[187]. Research and Development - The company is actively pursuing research and development in both pharmaceutical formulations and excipients, aiming to enhance its competitive edge in the market[30]. - The R&D pipeline includes 31 projects, with 14 active pharmaceutical ingredients and 17 excipients, focusing on cutting-edge fields such as oncology and diabetes[56]. - The company has maintained a stable R&D investment of over 10% of revenue for several years, with a research team of over 100 members and a laboratory area exceeding 2,000 square meters[56]. - The company is focusing on expanding its product offerings and enhancing its market presence through new drug registrations and certifications[46]. - The company is committed to continuous improvement in product quality and compliance with GMP standards throughout the production process[38]. Market Position and Strategy - The company anticipates continued stable growth in the pharmaceutical sector through 2025, driven by increasing health awareness and government investment in healthcare[27]. - The company has established a strong presence in over 60 countries, including the US, Japan, and Europe, due to its advanced manufacturing technology and quality assurance systems[29]. - The company is actively pursuing market expansion strategies, targeting new geographic regions to enhance its market presence[136]. - The company is considering strategic acquisitions to bolster its competitive position in the market[136]. - The company has a commitment to quality management, as evidenced by the role of the quality director in the supervisory board[168]. Governance and Compliance - The company has a comprehensive governance structure, including a board of directors and supervisory board[4]. - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3]. - The company adheres to strict governance practices in line with the Company Law and Securities Law, ensuring stable development and protection of investor rights[142]. - The company has established a performance evaluation and incentive mechanism for directors and senior management to ensure fairness and effectiveness in assessments[149]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[140]. Investor Relations - The company has a dedicated investor relations team to handle inquiries and disclosures[12]. - The company held multiple investor meetings throughout 2024, with a total of 301 participants in the April 25 meeting alone[135]. - The company is focusing on expanding its investor relations activities, as evidenced by the diverse range of institutional investors participating in the meetings[135]. - The company is committed to providing detailed insights into its financial and operational conditions during investor interactions[135]. - The company has been proactive in addressing investor inquiries and concerns through various communication channels[135]. Product Development and Innovation - The company has developed high-end excipients, with 103 registered varieties, of which 58 are in A status, particularly excipients for biological vaccines reaching advanced international standards[30]. - The company is actively expanding its product pipeline, with several new drug formulations in the registration process, indicating a commitment to innovation[40]. - The company has registered multiple new excipient products, all of which are in the production application stage[42]. - The company has introduced new products such as Indobufen Tablets and Vildagliptin Tablets, which are included in the National Medical Insurance Drug List[46]. - The company is pursuing a strategy of continuous innovation, as evidenced by the diverse range of products in various stages of development[41]. Risk Management - The company emphasizes quality control through process innovation and compliance management, aiming to enhance product competitiveness[127]. - The company acknowledges the potential for R&D risks due to market demand fluctuations and insufficient funding for product development[130]. - The company recognizes the impact of talent retention on R&D project progress, emphasizing the need for a stable and skilled workforce[131]. - The company is subject to regulatory requirements for drug production licenses, which must be renewed timely to avoid operational disruptions[131]. - The company faces risks related to concentrated procurement policies that may impact sales of key products, such as Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets[129]. Environmental and Social Responsibility - The company has received multiple awards for its commitment to safety and environmental protection, including national-level green factory recognition[74]. - The company has implemented wastewater treatment capabilities of 1,200 tons per day and air treatment of 38,000 cubic meters per hour[75]. - The pharmaceutical industry involves complex production processes with significant environmental impacts, and stricter future environmental regulations may increase operational costs[133]. Human Resources - The company has a total of 2,221 employees, with 971 in production, 442 in sales, and 492 in technical roles, reflecting a balanced workforce[183]. - The company emphasizes talent development through a three-tier training system, enhancing employee satisfaction and loyalty[185]. - The company has identified no significant risks during the supervisory activities of the supervisory board in the reporting period[182]. - The company has a dynamic compensation system based on performance, capability assessment, and job value, aiming to motivate employees and align their interests with the company's growth[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 696,028,386.21, representing a 17.79% increase compared to CNY 590,896,382.47 in the same period last year[6] - Net profit attributable to shareholders was CNY 125,775,709.52, a slight increase of 0.08% from CNY 125,669,473.12 year-on-year[6] - Basic earnings per share decreased by 30.56% to CNY 0.25, compared to CNY 0.36 in the same period last year[6] - Total operating revenue for the current period reached ¥696,028,386.21, an increase of 17.76% compared to ¥590,896,382.47 in the previous period[22] - Net profit for the current period was ¥125,775,709.52, slightly up from ¥125,669,473.12, reflecting a marginal increase of 0.08%[23] - The total comprehensive income for the current period was ¥125,775,709.52, slightly higher than ¥125,669,473.12 in the previous period[24] Cash Flow - The net cash flow from operating activities decreased by 38.15% to CNY 147,303,852.15, down from CNY 238,171,199.76 in the previous year[6] - Cash flow from operating activities generated a net amount of ¥147,303,852.15, down 38.19% from ¥238,171,199.76 in the prior period[26] - Net cash flow from investment activities was -$44.91 million, a decrease from -$126.37 million year-over-year[27] - Total cash inflow from financing activities was $56.78 million, compared to $9.00 million in the previous period[27] - Cash and cash equivalents increased by $153.21 million, up from $108.85 million year-over-year[27] - Cash outflow for investment activities totaled $246.16 million, an increase from $126.42 million year-over-year[27] - Cash outflow for financing activities was $5.96 million, compared to $11.95 million in the previous period[27] - Cash inflow from investment activities amounted to $201.25 million, up from $46,000 in the previous period[27] - Cash paid for the acquisition of fixed assets and intangible assets was $66.16 million, down from $86.42 million year-over-year[27] - Cash received from investment income was $1.25 million, unchanged from the previous period[27] Assets and Liabilities - Total assets increased by 3.43% to CNY 3,488,955,041.56 from CNY 3,373,131,232.71 at the end of the previous year[6] - Current assets totaled CNY 1,676,547,724.08, up from CNY 1,601,774,702.04, indicating an increase of about 4.7%[19] - Cash and cash equivalents rose to CNY 588,329,341.07 from CNY 443,307,337.44, marking a significant increase of approximately 32.7%[17] - The company's accounts receivable decreased to CNY 332,261,404.58 from CNY 350,502,639.39, a decline of about 5.2%[17] - Inventory levels remained stable, with a slight decrease from CNY 367,704,817.24 to CNY 366,528,565.07, a change of approximately -0.3%[17] - Total liabilities decreased from CNY 391,863,535.79 to CNY 294,960,082.37, representing a reduction of about 24.7%[19] - Long-term borrowings increased by 43.61% to CNY 183,696,080.00, attributed to stock repurchase loans and project loans[10] - Long-term borrowings increased to CNY 183,696,080.00 from CNY 127,913,000.00, reflecting a growth of approximately 43.6%[19] - Total liabilities amounted to ¥839,592,801.00, a decrease of 0.96% from ¥846,401,371.85[20] - Total equity attributable to shareholders reached ¥2,649,362,240.56, an increase of 4.83% from ¥2,526,729,860.86[20] Research and Development - The company reported a 54.19% increase in R&D expenses, totaling CNY 63,106,394.07, compared to CNY 40,928,107.97 in the previous year[10] - Research and development expenses increased to ¥63,106,394.07, a rise of 54.36% compared to ¥40,928,107.97 in the previous period[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,861[12] - The company reported a total of 125,061,391 shares with restricted sales at the end of the period, up from 124,305,686 shares at the beginning[15] Other Information - The company experienced a significant increase of 3330.65% in special reserves, amounting to CNY 295,936.61, due to increased safety investment reserves[10] - The company reported a decrease in other income by 72.23%, totaling CNY 6,907,915.13, primarily due to a reduction in government subsidies received[10] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[16]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截 ...